Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ENPP3 | O14638 | 7/20 | 0.52 |
| ▸ | ALPL | P05186 | 7/20 | 0.52 |
| ▸ | XIAP | P98170 | 7/20 | 0.52 |
| ▸ | ENPP1 | P22413 | 3/20 | 0.52 |
| ▸ | MAPT | P10636 | 2/20 | 0.42 |
| ▸ | MAP3K14 | Q99558 | 3/20 | 0.40 |
| ▸ | ELANE | P08246 | 2/20 | 0.36 |
| ▸ | AR | P10275 | 1/20 | 0.34 |
| ▸ | IKBKB | O14920 | 2/20 | 0.34 |
| ▸ | IKBKE | Q14164 | 1/20 | 0.34 |
| ▸ | TP53 | P04637 | 1/20 | 0.33 |
| ▸ | CARM1 | Q86X55 | 1/20 | 0.33 |
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL508348 | 0.87 | ENPP3 (0.45) | ENPP3ALPLXIAPENPP1MAPT | |
| SCHEMBL10254343 | 0.87 | ENPP3 (0.45) | ENPP3ALPLXIAPENPP1MAPT | |
| SCHEMBL508806 | 0.82 | MAPT (0.41) | ENPP3ALPLXIAPENPP1MAPT | |
| SCHEMBL14540763 | 0.82 | MAPT (0.39) | ENPP3ALPLXIAPENPP1MAPT | |
| SCHEMBL10250575 | 0.76 | MAPT (0.46) | ENPP3ALPLXIAPENPP1MAPT | |
| SCHEMBL14303592 | 0.76 | KCNH2 (0.44) | ENPP3ALPLXIAPENPP1MAPT | |
| SCHEMBL509286 | 0.74 | EPAS1 (0.40) | ENPP3ALPLXIAPENPP1AR | |
| SCHEMBL508819 | 0.72 | KCNH2 (0.47) | ENPP3ALPLXIAPENPP1MAPT | |
| SCHEMBL14540679 | 0.72 | KCNH2 (0.47) | ENPP3ALPLXIAPENPP1MAPT | |
| SCHEMBL508698 | 0.72 | MAPT (0.41) | ENPP3ALPLXIAPENPP1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1762567-B1 | Pyrazole derivatives for treating HIV | PFIZER LTD (GB) | 2012-05-02 | — | — | EP | disclosed |
| US-20120029192-A1 | Pyrazole Derivatives | PFIZER INC | 2012-02-02 | — | — | US | disclosed |
| US-20120029192-A1 | Pyrazole Derivatives | PFIZER INC | 2012-02-02 | — | — | US | disclosed |
| US-20120029192-A1 | Pyrazole Derivatives | PFIZER INC | 2012-02-02 | — | — | US | disclosed |
| US-8063044-B2 | Pyrazole derivatives | PFIZER INC. (US) | 2011-11-22 | — | — | US | disclosed |
| US-8063044-B2 | Pyrazole derivatives | PFIZER INC. (US) | 2011-11-22 | — | — | US | disclosed |
| US-8063044-B2 | Pyrazole derivatives | PFIZER INC. (US) | 2011-11-22 | — | — | US | disclosed |
| US-20090215712-A1 | PYRAZOLE DERIVATIVES | PFIZER INC | 2009-08-27 | — | — | US | disclosed |
| US-20090215712-A1 | PYRAZOLE DERIVATIVES | PFIZER INC | 2009-08-27 | — | — | US | disclosed |
| US-20090215712-A1 | PYRAZOLE DERIVATIVES | PFIZER INC | 2009-08-27 | — | — | US | disclosed |
| EP-1762567-A1 | Pyrazole derivatives for treating HIV | Pfizer Limited (GB) | 2007-03-14 | — | — | EP | disclosed |
| US-7157468-B2 | Pyrazole derivatives | PFIZER INC. (US) | 2007-01-02 | — | — | US | disclosed |
| US-7157468-B2 | Pyrazole derivatives | PFIZER INC. (US) | 2007-01-02 | — | — | US | disclosed |
| US-7157468-B2 | Pyrazole derivatives | PFIZER INC. (US) | 2007-01-02 | — | — | US | disclosed |
| US-7109228-B2 | Pyrazole derivatives | AGOURON PHARMACEUTICALS, INC. (US) | 2006-09-19 | — | — | US | disclosed |
| US-20060020012-A1 | Pyrazole derivatives | PFIZER INC | 2006-01-26 | — | — | US | disclosed |
| EP-1556381-A1 | PYRAZOLE AMIDES FOR TREATING HIV INFECTIONS | Pfizer Limited (GB) | 2005-07-27 | — | — | EP | disclosed |
| US-20050004129-A1 | Pyrazole derivatives | PFIZER, INC. | 2005-01-06 | — | — | US | disclosed |
| WO-2004029051-A1 | PYRAZOLE AMIDES FOR TREATING HIV INFECTIONS | PFIZER LIMITED (GB) | 2004-04-08 | — | — | WO | disclosed |
| US-20030100554-A1 | Pyrazole derivatives | JONES LYN HOWARD (GB) | 2003-05-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090215712-A1 | PYRAZOLE DERIVATIVES | RRM2B, REV1, RRM2 | ENPP3 750/4885ALPL 3566/4885XIAP 3386/4885 |
| US-20060020012-A1 | Pyrazole derivatives | PDCD11, RTF1, REV1 | ENPP3 1020/4885ALPL 2968/4885XIAP 3542/4885 |
| US-20050004129-A1 | Pyrazole derivatives | RTF1, RRM2B, RRM2 | ENPP3 1100/4885ALPL 2537/4885XIAP 3123/4885 |
| US-20120029192-A1 | Pyrazole Derivatives | POLRMT, PDCD11, DPYD | ENPP3 632/4885ALPL 2083/4885XIAP 2856/4885 |
| US-20030100554-A1 | Pyrazole derivatives | REV1, SARS1, CYP2F1 | ENPP3 968/4885ALPL 2483/4885XIAP 3624/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.